Based on these findings, we suggest that increased AKT activity due to decreased ERG mitigates the efficacy of AR-targeted therapies to a greater extent in T:E fusion PCa and that men with T:E fusion–positive tumors may most benefit from the addition of an AKT inhibitor to AR-targeted therapy. The gene discussed is AKT1; the disease is posterior cortical atrophy.